You are here

Adderall Gains Adult Indication

BASINGSTOKE, England and PHILADELPHIA, Pennsylania, August 12/PRNewswire/ -- Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that its leading treatment for Attention Deficit Hyperactivity Disorder (ADHD), Adderall XR(R) (mixed salts of a single-entity amphetamine) has been approved by the US FDA as a once-daily treatment for adults.

Adderall XR net sales for the 6 months to June 2004 were US $283 million, 30% up on the same period in 2003.

Shire will begin promoting the adult indication in the US immediately.

In addition, the FDA has confirmed to Shire that new 40mg, 50mg and 60mg dose strengths of Adderall XR will require additional clinical data for approval.

Shire Chief Executive, Matthew Emmens commented:

"Adderall XR is the most prescribed brand for the treatment of ADHD in the US, a market that expanded by 20% over last year. The impact of ADHD on people's ability to carry out their daily lives and work effectively is being increasingly acknowledged and the market for adult patients could ultimately be double that for pediatric patients. Although we have not been able to promote adult usage, many physicians have been prescribing ADDERALL XR for adults 'off label' for some time. Adults represent 15 - 20% of the current ADDERALL XR total prescriptions. We can now support the expansion of this adult market segment."

Studies have shown that up to 65 per cent of children with ADHD continue to exhibit symptoms into adulthood and an estimated 4.4 per cent of the US adult population is affected by ADHD.(i) If left untreated, this disorder may lead to other psychological difficulties, such as depression, as well as occupational and social disability.(ii) Appropriate diagnosis and treatment of ADHD in adults helps improve self-esteem, work performance and skills, educational attainment and social competencies.(iii) Over 8 million adults in the US may exhibit the symptoms of ADHD, while only an estimated 600,000 are being treated.

Dr Richard H. Weisler, adjunct Professor of Psychiatry at the University of North Carolina, Chapel Hill (UNC) School of Medicine and principal investigator for Adderall XR studies in adults, commented:

"ADHD in adult patients may significantly impair a person's social and family relationships, as well as his or her career. Stimulant therapies, such as Adderall XR, have been used successfully in patients for more than 60 years. It's an important step that Adderall XR is the first stimulant to be approved for use in adults."

About Adderall XR
Adderall XR is a once-daily extended release, single-entity amphetamine product available in 5mg, 10mg, 15mg, 20mg, 25mg and 30mg. The Adderall XR capsule contains two types of drug-containing beads designed to give a double-pulsed delivery of amphetamines, which prolongs the release of amphetamine from Adderall XR compared to the conventional Adderall (immediate-release) tablet formulation.

The US FDA approved Adderall XR in November 2001 for the treatment of ADHD in children.

Source: Shire Pharmaceuticals

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM